Stock Scorecard

Stock Summary for Alzamend Neuro Inc (ALZN) - $0.68 as of 5/5/2025 5:10:45 PM EST

Total Score

11 out of 30

Safety Score

20 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ALZN

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ALZN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ALZN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ALZN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ALZN (20 out of 100)

Stock Price Rating (Max of 10) 1
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 1
Analyst Buy Ratings (Max of 5) 2
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for ALZN

Alzamend Neuro ( ALZN ) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? 4/8/2025 1:55:00 PM
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital - Alzamend Neuro ( NASDAQ:ALZN ) 3/18/2025 12:00:00 PM
Bitcoin Eyes $73K Without New Catalyst: 10x Research; XPeng Plans $13.8B Humanoid Robot Push; SpaceX Partners With Airtel To Launch Starlink In India - Top Headlines While The U.S. Slept 3/11/2025 3:11:00 PM
EXCLUSIVE: Alzamend Neuro To Launch Phase 2 Study For Lead Drug For PTSD Patients In Late 2025 To Assess Lithium Delivery Benefits - Alzamend Neuro ( NASDAQ:ALZN ) 3/11/2025 11:33:00 AM
EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025 - Alzamend Neuro ( NASDAQ:ALZN ) 2/25/2025 12:30:00 PM
EXCLUSIVE: Alzamend Neuro Says Tesla Dynamic Completes Head Coil To Measure Brain Structure Lithium Levels - Alzamend Neuro ( NASDAQ:ALZN ) 2/19/2025 12:30:00 PM
Has Alzamend Neuro ( ALZN ) Outpaced Other Medical Stocks This Year? 1/23/2025 2:40:00 PM
EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential - Alzamend Neuro ( NASDAQ:ALZN ) 11/19/2024 12:30:00 PM
Bitcoin Rises While Ethereum, Dogecoin Stay Flat Amid Stock Reversal; ASML Struggles, Nvidia and AMD Recover; Stellantis Recalls 21K Hybrid SUVs Over Brake Pedal Issue - Top Headlines Today While US Slept 10/16/2024 1:10:00 PM
EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's - Alzamend Neuro ( NASDAQ:ALZN ) 10/16/2024 11:30:00 AM

Financial Details for ALZN

Company Overview
Ticker ALZN
Company Name Alzamend Neuro Inc
Country USA
Description N/A
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 1/31/2025
Next Earnings Date N/A

Stock Price History
Last Day Price 0.68
Price 4 Years Ago 285.00
Last Day Price Updated 5/5/2025 5:10:45 PM EST
Last Day Volume 107,727
Average Daily Volume 127,067
52-Week High 7.30
52-Week Low 0.63
Last Price to 52 Week Low 7.94%

Valuation Measures
Trailing PE N/A
Industry PE 32.04
Sector PE 37.03
5-Year Average PE -410.32
Free Cash Flow Ratio 1.33
Industry Free Cash Flow Ratio 19.19
Sector Free Cash Flow Ratio 29.42
Current Ratio Most Recent Quarter 5.44
Total Cash Per Share 0.51
Book Value Per Share Most Recent Quarter 0.60
Price to Book Ratio 1.28
Industry Price to Book Ratio 7.60
Sector Price to Book Ratio 21.93
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 101.19
Sector Price to Sales Ratio Twelve Trailing Months 28.34
Analyst Buy Ratings 1
Analyst Strong Buy Ratings 0

Share Statistics
Total Shares Outstanding 6,597,500
Market Capitalization 4,486,300
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 33.14%
Reported EPS 12 Trailing Months -134.51
Reported EPS Past Year -1.84
Reported EPS Prior Year -14.21
Net Income Twelve Trailing Months -4,226,937
Net Income Past Year -9,947,746
Net Income Prior Year -14,878,167
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet
Total Cash Most Recent Quarter 3,358,135
Total Cash Past Year 376,048
Total Cash Prior Year 5,140,859
Net Cash Position Most Recent Quarter 3,013,242
Net Cash Position Past Year 75,334
Long Term Debt Past Year 300,714
Long Term Debt Prior Year 335,303
Total Debt Most Recent Quarter 344,893
Equity to Debt Ratio Past Year 0.00
Equity to Debt Ratio Most Recent Quarter 0.91
Total Stockholder Equity Past Year -2,594,185
Total Stockholder Equity Prior Year 3,045,503
Total Stockholder Equity Most Recent Quarter 3,449,783

Free Cash Flow
Free Cash Flow Twelve Trailing Months -7,633,431
Free Cash Flow Per Share Twelve Trailing Months -1.16
Free Cash Flow Past Year -8,417,236
Free Cash Flow Prior Year -8,923,152

Options
Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD -0.06
MACD Signal -0.06
20-Day Bollinger Lower Band 0.54
20-Day Bollinger Middle Band 0.95
20-Day Bollinger Upper Band 1.36
Beta -0.19
RSI 38.64
50-Day SMA 51.16
150-Day SMA 0.00
200-Day SMA 118.68

System
Modified 5/5/2025 5:10:46 PM EST